- About
- PsychU For You
- Topics
- Events
- Content
Live Event – All Hands On Deck In The Treatment Of Major Depressive Disorder (MDD): A Focus On Measurement-Based Care In Psychiatry & Primary Care
About This Event
Live Event – All Hands On Deck In The Treatment Of Major Depressive Disorder (MDD): A Focus On Measurement-Based Care In Psychiatry & Primary Care
This is a Live Event for PsychU members in Connecticut.
Given the current state of affairs, primary care providers are increasingly treating patients with Major Depressive Disorder (MDD). During this panel presentation, Drs. Joseph Goldberg, and C. Brendan Montano will be discussing the prevalence and burden of MDD within the Tri-State region, with an emphasis on Connecticut, and the impact of COVID-19 on MDD. Additionally, the speakers will discuss barriers faced by primary care providers and include the perspectives and expertise from psychiatrists. Finally, the presenters will consider the potential role of measurement-based care, focusing on the strategies incorporated in their practices and discussing methods of collaboration.
Objectives:
- Discuss the prevalence and burden of Major Depressive Disorder (MDD) locally and nationally, including the impact of COVID-19
- Identify gaps between primary care and psychiatry within treatment of MDD
- Understand the potential role and importance of measurement-based care (MBC)
- Consider methods of collaboration that may improve outcomes for patients with MDD
Ruth’s Chris Steak House – Newington
2513 Berlin Turnpike
Newington, CT 06111 United States + Google Map(860) 666-2202 View Venue Website
Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai
MoreJoseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”
C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut
MoreDr. Montano is Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut, where he also holds a private practice in internal medicine, specializing in preventative medicine and mood disorders. In addition, he is an attending physician at Middlesex Memorial Hospital in Middletown, Connecticut.
Alyssa Weers, PharmD (OPDC)
Clinical & Scientific Liaison
Registration
PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients. NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.
- PsychU For You
